Clinical Trial Detail

NCT ID NCT04173507
Title Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Southwest Oncology Group
Indications

lung non-small cell carcinoma

adenosquamous lung carcinoma

lung non-squamous non-small cell carcinoma

Therapies

Avelumab + Talazoparib

Age Groups: adult child senior

Additional content available in CKB BOOST